This trial is active, not recruiting.

Conditions asthma, allergy
Sponsor University of Wisconsin, Madison
Collaborator National Institutes of Health (NIH)
Start date October 1998
End date May 2018
Trial size 300 participants
Trial identifier NCT00204841, 1998-129, P01HL070831


Although asthma is likely to be a heterogeneous disease or syndrome, three factors and/or events repetitively emerge for their ability to significantly influence asthma inception in the first decade of life: immune response aberrations, which appear to be defined best by the concept of cytokine dysregulation; lower respiratory tract infections (in particular RSV); and some form of gene by environment interaction that needs to occur at a critical time period in the development of the immune system or the lung. It remains to be firmly established, however, how any one or all of these factors, either independently or interactively, influence the development of childhood asthma. Thus, our efforts to determine and define the importance of these three factors to asthma pathogenesis are the focus and goal of this current grant application.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Evaluate the children longitudinally for the inception and progression of asthma.
time frame: Birth through puberty.

Eligibility Criteria

Male or female participants up to 2 minutes old.

Inclusion Criteria: - children who had one or more parent with a history of allergy or asthma Exclusion Criteria: - pre term infants - low birth weight infants - respiratory distress at birth

Additional Information

Official title Rhinovirus Infection and Asthma in Childhood and Adolescents
Principal investigator Robert F Lemanske, Jr., MD
Description No more description necessary.
Trial information was received from ClinicalTrials.gov and was last updated in November 2015.
Information provided to ClinicalTrials.gov by University of Wisconsin, Madison.